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Abstract
Systemic lupus erythematosus is a chronic autoimmune disease that affects 
mostly women. The kidneys are involved in 50% of patients causing a high degree 
of disease morbidity and mortality with poor prognosis. Early diagnosis of lupus 
nephritis with prompt therapy correlates with a better outcome. The renal biopsy 
provides important informations to clinicians to monitor the patients. The patterns 
of glomerular lesion, degree of activity and chronicity of the disease and extent 
of lesions to the tubulointerstitial and vascular compartments are fundamental 
information for the clinician to decide the most appropriate treatment. In order to 
correlate the kidney disease with clinical manifestations and patient outcome the 
glomerular lesions are classified according to International Society of Nephrology 
and Renal Pathology Society Classification (ISN/RPS). The definition of active and 
chronic lesions was introduced by studies conducted at National Institute of Health 
(NIH). The ISN/RPS classification and NIH indices have recently been revised by a 
series of retrospective validation studies to improve and minimize the controversial 
aspects.
Keywords: Systemic lupus erithematosus, lupus nephritis, renal biopsy, ISN/RPS 
classification, NIH activity and chronicity indices, patients management, prognosis
1. Introduction
Systemic lupus erythematosus (SLE) is a chronic multisystem autoimmune 
disease that frequently involve kidneys in women. The development of the disease is 
related to exposure to environmental factors in individuals with genetic predisposi-
tion. It is characterized by loss of tolerance against nuclear autoantigens, lympho-
proliferation, polyclonal autoantibody production, immune complex disease and 
multiorgan tissue inflammation [1]. The affected organs include skin, joints, heart, 
lungs, kidneys, central nervous system and serous membranes. The disease involves 
a sequence of manifestations such as arthritis, serositis, chronic fatigue, skin rashes, 
glomerulonephritis, neurological involvement and hematological abnormalities 
[2]. SLE is the most frequent cause of secondary glomerular disease [3–5]. Lupus 
nephritis (LN) as a disease usually develops early in the clinical course of SLE 
in up to 50% of patients. The development of effective diagnostic tests and the 
introduction of new therapies has shown an improvement in the survival of patients 
with SLE. However, SLE patients still have a higher risk of death than the general 
population, especially patients with LN. Lupus glomerulonephritis with intense 
activity requires greater immunosuppression with increased risk of death from 
opportunistic infections. On the other hand, long-term treatment with high-dose 
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of corticosteroids is a risk factor for coronary atherosclerosis and cardiovascular 
disease [1, 6]. Glomerular immune complexes can activate complement and 
engage leukocyte Fc receptors to initiate renal inflammation and injury [1]. LN has 
very pleomorphic clinical and morphologic expressions. Clinical findings range 
from asymptomatic hematuria and proteinuria to nephrotic syndrome or rapidly 
progressive renal failure [7].
2. Renal biopsy
The renal biopsy is the gold standard for the diagnosis of LN, providing 
important information to the clinician for the management of the patients [7–9]. 
A diagnosis of SLE is based on clinical systemic features and serologic tests attend-
ing the American College of Rheumatology (ACR) criteria for SLE [10]. However, 
it is not uncommon that the renal biopsy shows morphologic expressions that is 
very suspicious or conclusive of LN before extrarenal manifestations are evident 
[11]. The renal biopsy provides an important information about the morphology 
and severity of the lesions, their classification, grades of activity and chronicity of 
the disease. With the appearance of any signs or symptoms of kidney disease such 
as hematuria, proteinuria, nephrotic syndrome or renal insufficiency the renal 
biopsy should be performed. Repeat kidney biopsies should also be done for clinical 
indications due to SLE flare, persistent proteinuria or declining renal function. 
The role of the renal biopsy in diagnosis, treatment, management, and follow-up 
of LN is critical, although to predict the outcome has been a matter of controversy 
[1, 7, 8]. Considering the importance of the biopsy making the treatment decision 
and determining the prognosis, it is essential to assess renal histopathology with 
high accuracy [9, 12, 13]. LN can affect all compartments of the kidney including 
glomeruli, tubules, interstitium and blood vessels. The analysis of the renal lesions 
is based on light microscopy (LM) associated with the immunofluorescence (IF) 
and electron microscopy (EM) findings [11].
3. Glomerular, tubulointerstitial and vascular lesions
The glomeruli are the most affected compartment in the LN. The initial injury 
is related to immune deposits in the mesangium and/or capillary loops. Large 
subendothelial deposits can be easily seen by LM. The distribution of deposits in the 
mesangium and/or glomerular capillaries defines the morphological pattern of the 
disease and consequently clinical manifestations. Some cases have only mesangial 
deposits, and others have deposits in the mesangium and in the capillary loops. 
Deposits in the capillary loops can be intramembranous, subendothelial (between 
endothelial cells and glomerular basement membrane) or subepithelial (between 
podocytes and glomerular basement membrane). Large subendothelial deposits 
characterize the wire loops and determine intense thickening of the glomerular 
basement membrane with occlusion of capillary loops (Figure 1). Immune deposits 
with complement activation determines an inflammatory reaction with prolifera-
tion of resident cells and exudation of mononuclear cells and polymorphonuclear 
neutrophils. Mesangial deposits stimulate proliferation of mesangial cells and 
deposition of mesangial matrix. Subendothelial deposits in capillary loops stimulate 
endothelial proliferation, and subepithelial deposits determines thickening of 
the GBM without significant cellular proliferation. Capillary involvement by the 
inflammatory response may result in segmental glomerular necrosis and adjacent 
cellular crescents. Prolonged glomerular injury result in segmental and/or global 
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scarring. The IF staining is variable. IgG is the most frequent immunoglobulin 
(Figure 2), usually associated with deposits of C1q and C3. IgM and IgA deposits 
may also be present. Fibrin deposits are frequent in areas of necrosis and in associa-
tion with active crescents. The IF staining is called the full house when there is 
deposition of the three immunoglobulins, C1q and C3. This staining pattern is very 
useful for diagnosing LN. The EM confirms the IF findings showing since small 
mesangial electron dense deposits to large and abundant deposits in the mesangium 
with extension to capillary loops. Immune deposits limited to the mesangium 
are associated with mild clinical signs and symptoms. The presence of deposits 
in the capillary loops, especially in the subendothelial space, is related to more 
harmful forms of the disease. Anti-dsDNA and anti-C1q antibodies correlate with 
Figure 1. 
Glomerulus with intense global hypercellularity and subendothelial hyaline deposits in peripheral capillary 
loops (wire loops). Masson thricrome 400x.
Figure 2. 
Granular deposits of IgG in the mesangium and capillary loops. IF-400x.
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subendothelial deposits that stimulate endothelial proliferation and glomerular 
necrosis. The most severe form of LN are cases of diffuse proliferative nephritis 
that show voluminous subendothelial deposits with high correlation with disease 
activity. Furthermore, during the course of the disease, LN can undergo transfor-
mations. Purely mesangial injuries can evolve to more severe mesangioendothelial 
proliferative disease with damage of capillary loops. After treatment, severe LN 
with endothelial proliferation can turn into mesangial proliferative lesion [7, 11].
Tubulointerstitial lesions are found in all types of glomerular lesions, although 
is more frequent in the most severe forms of proliferative LN. The lesions result 
from the autoimmune inflammatory activity of the disease and/or prolonged 
periods of proteinuria [11]. The acute phase is characterized by edema and inflam-
matory infiltrate with a predominance of mononuclear cells. Immune deposits are 
detected by IF and EM mainly in the tubular basement membrane and peritubular 
capillaries in 50% of the patients (Figure 3). Immunoglobulins are associated 
with complement components C1q and C3 in most cases. There was no correlation 
between prevalence of deposits and the severity of interstitial inflammation, sug-
gesting that the immune complexes are not involved in the pathogenesis of inter-
stitial nephritis in SLE [11, 14]. The predominance of T lymphocytes, CD4 or CD8, 
with frequent presence of monocytes and NK cells suggests cellular immunity. 
While several mechanisms may play an initial role, interstitial T cells and mono-
cytes may be important determinants of pathogenesis of interstitial nephritis, and 
monocytes may be the major factor in the chronic injury and progression of LN 
[15]. On the other hand, nephrotic proteinuria also induces changes in the tubular 
cells due to active and excessive resorption of filtered proteins and lipoproteins by 
the proximal tubules [11]. After a prolonged period of damage, tubular atrophy 
and interstitial fibrosis characterize the chronic phase of the disease. Active and 
severe tubulointerstitial injury is most common in severe diffuse proliferative LN. 
The severity of interstitial inflammation correlated with the degree of renal insuf-
ficiency and was an accurate prognostic indicator of progressive deterioration of 
renal function. Many studies have shown an association between tubulointerstitial 
damage and a poor renal outcome in LN and in order to avoid progression to end 
Figure 3. 
Granular deposits of C1q in tubular basement membrane and peritubular spaces. IF-400x.
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stage renal disease some studies suggest an early intervention before the develop-
ment of interstitial fibrosis [15–18].
A variety of vascular lesions are encountered in renal biopsies of patients with 
SLE: uncomplicated vascular immune deposits, noninflammatory necrotizing vas-
culopathy, true renal vasculitis, thrombotic microangiopathy and arteriosclerosis. 
The interlobular arteries and arterioles are the most involved vessels [11, 19–21]. 
Large study with 285 patients with LN found vascular lesion in 79 (27.7%): 9.47% 
with noninflammatory necrotizing vasculopathy, 8.42% with thrombotic microan-
giopathy, 7.02% with arteriosclerosis and 2.81% with true vasculitis [20]. Wu  
et al [21] studying 341 patients with LN found 81.8% of vascular injury, including 
74.19% of uncomplicated vascular immune deposits, 24.5% of arteriosclerosis, 
17.59% of thrombotic microangiopathy, 3.81% of noninflammatory necrotizing 
vasculopathy and 0.59% of true vasculitis. The inclusion of cases of uncomplicated 
vascular immune deposits explains the higher incidence of vascular lesions in 
this study. Uncomplicated vascular immune deposits are the most common lesion 
and do not significantly affect prognosis. This type of injury shows deposits of 
immunoglobulins and complement in the small arteries and arterioles, without 
any inflammatory process and impairment of vascular lumen. The noninflamma-
tory necrotizing vasculopathy determines severe vascular narrowing by abundant 
eosinophilic material constituted by immune deposits, plasma proteins and fibrin 
insudation in the vessel wall. There are also degenerative changes and loss of 
endothelial cells and myocytes. This is a form of vascular lesion associated to more 
severe forms of glomerular lesion, and is less common than uncomplicated vascular 
immune deposits. The necrotizing vasculopathy has a poor prognosis with a high 
degree of disease progression. A true renal vasculitis, with inflammatory infiltrate 
and necrosis of the vascular wall, is the least common vascular lesion in the LN. 
This kind of lesion is very severe with an ominous prognosis and need an aggres-
sive immunosuppressive therapy. The thrombotic microangiopathy is characterized 
by myointimal proliferation of the small vessels, with a pattern of “onion skin”, 
that complicates with thrombosis. In patients with SLE this vascular lesion occurs 
in association with hemolytic-uremic syndrome, antiphospholipid syndrome and 
malignant hypertension. Arteriosclerosis is a degenerative non-immunological 
vascular lesion characterized by fibrous thickening of the intima of the arteries 
without necrosis, proliferation or thrombosis. This lesion is common in LN due 
to the high prevalence of risk factors for arteriosclerosis in lupus patients such 
as hypertension, hyperlipidemia and prolonged use of corticosteroids. Vascular 
lesion can occur in any type of glomerular injury, but they are more frequent in 
the more active glomerulitis with mesangial and glomerular capillaries involve-
ment [11, 19, 21]. Renal vascular lesions, specially of the necrotizing, vasculitic or 
thrombotic type adversely affects renal outcome with a higher rate of progression 
to renal failure [11, 19–21]. At the time of renal biopsy, patients with vascular 
lesion had higher levels of serum creatinine than patients without vascular lesion 
(2.2 mg/dl vs. 1.2 mg/dl). The probability of a kidney survival at 5 and 10 years 
was 74.3% and 58.0% in patients with vascular lesion, compared with 89.6% and 
85.9% in patients without vascular lesion, respectively [20].
4.  International Society of Nephrology and Renal Pathology Society 
Classification (2003)
The classifications of LN are based on glomerular morphologic lesions in differ-
ent classes of LN and aim to identify patients at risk of progressing to chronic renal 
failure.
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The morphological changes are based mainly under LM, although the combined 
analysis of IF and EM provide more effective study. The original World Health 
Organization (WHO) classification, formulated in 1974, defined 5 classes: Classes 
I-Normal glomeruli, II-Pure Mesangial Proliferation, III-Focal and segmental 
proliferative GN (<50% of glomeruli), IV-Diffuse Proliferative GN (≥50% of 
glomeruli) and V-Membranous GN. In 1995, the WHO classification was modified 
by the inclusion of subclasses enphasizing active and chronic lesions. However, 
the introduction of many subclasses has made it difficult to apply in practice. The 
subclasses of the membranous form of LN (class V) with proliferative lesions of 
class III (Vc) and class IV (Vd) were very controversial. The class V with additional 
proliferative features (Vc and Vd) showed a worse prognosis than pure class V, 
demonstrating that the prognosis was related to proliferative lesions and not to 
class V. These subcategories were eliminated, and instead, such complex lesions 
should be diagnosed as association of class V with classes III or IV [11]. The WHO 
classification has more recently evolved into the 2003 International Society of 
Nephrology and Renal Pathology Society classification (ISN/RPS) [22] (Table 1). 
The ISN/RPS nomenclature described only the immune-complex LN, not address-
ing other lesions such as thrombotic microangiopathy and podocytopathies. The 
ISN/RPS system classifies LN on the basis of where immune complexes accumulate 
in glomeruli, the presence or absence of mesangial or endocapillary proliferation, 
the overall extent of glomerular involvement (focal or diffuse; global or segmental) 
and whether glomerular injury is active (inflammatory) or chronic (sclerotic).
The schema ISN/RPS retains the major criteria of WHO classification with a 
revision and/or inclusion of pathologic details for each class. The “normal”category 
of the class I of WHO was eliminated, being replaced by the presence of mesangial 
deposits by IF and/or EM with normal LM. Class II besides deposits by IF or EM 
presents mesangial proliferation by LM. Classes III and IV present both mesangial 
and capillary deposits with endocapillary proliferation, and are separated based 
on the percentage of glomeruli affected by active and chronic lesions. The most 
Classes Type of Lesion
Class I-Mesangial LN Normal LM, deposits IF or EM
Class II-Mesangial 
Proliferative LN
Mesangial hipercellularity and immune deposits by IF or EM
Class III-Focal LN
III (A)-active lesions
III (A/C)-active and chronic 
lesions
III (C)-chronic lesions
< 50% glomeruli affected by segmental or global endo and/or 
extracapillary proliferation, subendothelial deposits, necrosis and 
crescents. Active and chronic lesions.
Class IV-Diffuse LN
IV-S (A) or IV-G (A)-active 
lesions
IV-S (A/C) or IV-G (A/C)-
active and chronic lesions
IV-S (C) or IV-G 
(C)-glomerular scars
≥50% glomeruli affected by segmental or global endo and/or 
extracapillary proliferation, subendothelial deposits, necrosis and 
crescents. Active and chronic lesions.
Class V-Membranous LN Subepithelial deposits with thickening of GBM
Class VI-Advanced sclerosing 
LN
90% sclerosed glomeruli. Absence of residual activity.
Table 1. 
International Society of Nephrology and Renal Pathology Society Classification of lupus Nephritis-2003  
(ISN/RPS).
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controversial aspect was the introduction of a subdivision of class IV based on 
whether the lesions are predominantly segmental or global [23]. Previous studies 
have suggested that a subgroup of LN with severe segmental lesions involving most 
of the glomeruli, may have a different pathogenesis than the global proliferative 
lesions of class III or IV. These severe segmental lesions often had necrosis and 
crescents, similar to pauci-immune necrotizing and crescentic GN. About 20% of 
patients with apparent necrotizing and crescentic LN, with rare or absent subendo-
thelial deposits and without significant endocapillary proliferation, have positive 
ANCA suggesting a coexistence of LN and ANCA-associated necrotizing and 
crescentic GN [24]. Features of activity and chronicity was clearly delineated in the 
subcategories of class III and IV. Class IV has a higher risk of progression to chronic 
renal failure and large subendothelial deposits, necrosis and crescents have a worse 
prognosis. Due to the higher frequency of biopsied patients with more aggressive 
kidney injury, most series show a higher percentage of class IV [11]. The class VI 
was defined with glomerular sclerosis ≥90% of glomeruli without residual activ-
ity. Severe tubular atrophy, interstitial fibrosis, inflammation, and arteriosclerosis 
usually accompany the glomerular sclerosis. Chronic lesions, such as segmental or 
global sclerosis, are interpreted as sequelae of previous more aggressive lesions in 
the current classification. Thus, a segmentally sclerosing lesion producing an adhe-
sion to Bowman’s capsule, most likely represents an organization of a lesion with 
endothelial proliferation and/or necrosis and crescents, and should be interpreted 
as a chronic lesion of class III or IV. Globally sclerosed glomeruli can be particularly 
challenging, because ischemic collapse of the glomerular tuft with collagenous 
material in Bowman’s space occur with aging and benign nephrosclerosis. This 
kind of lesion overlaps with sclerosed glomerulus with a fibrous crescent after an 
inflammatory process. Excess cells in the collagenous area, evidence of proliferative 
injury in the glomerular tuft with adhesion to the retracted and lamellate Bowman’s 
capsule can help distinguish sclerosis due to LN from other causes of sclerosis [8].
Therefore, immune complex formation in the mesangium causes class I and II 
lesions, subendothelial deposits causes classes III and IV and subepithelial deposits 
occur in class V lesions.
5. Activity and chronicity indices
It has been known that immunosuppressive therapy is capable of reducing 
the amount of immune deposits and the degree of inflammatory process in the 
kidney. However, reduction of histological activity was not always accompanied 
by clinical improvement and, on the other hand, active lesions on the biopsy may 
be associated with a silent clinical presentation. These findings demonstrate the 
importance of renal biopsy in monitoring patients. Investigators have attempted to 
analyze renal biopsy specimens of LN with respect to active and chronic features as 
predictors of outcome and guides to therapy. Active lesions are potentially treatable 
and only the most severe ones become chronic, whereas chronic lesions represent 
irreversible damage with great impact in the outcome [25]. The concept of activity 
and chronicity indices was adopted in the studies of National Institutes of Health 
(NIH) (Table 2). According to this system, the activity (AI) and chronicity indices 
(CI) are graded on a scale of 0 to 24 and 0 to 12, respectively, by calculating the 
sum of individual scores (0 to 3+). In a group of patients with diffuse prolifera-
tive disease (Class IV), Austin et al [25] found that AI is moderately predictive of 
outcome, with 60% 10-year survival with AI greater than 12. Another study [26] 
showed 40% of impairment of renal function in 4 years with AI > 12 compared to 
7% in the group with AI < 12. The CI was more predictive of renal outcome than 
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AI, demonstrating a 100% 10-year survival with CI ≤ 1, 68% with CI of 2 or 3 and 
32% with CI ≥ 4. Although individual activity scores do not show predictive value 
for disease progression, all the scores of CI were individually predictive of renal 
failure, particularly tubular atrophy [25]. A combination of different scores also 
shows impact on the prognosis. There are a high risk of doubled creatinine with a 
combination of two scores, such as more than 50% of cellular crescents and moder-
ate to severe interstitial fibrosis. Patients with severe disease treated with aggressive 
immunossuppression showed that AI > 7 and CI > 3 have a high risk of progression 
[27]. More than 5o% of crescents are a very ominous morpological finding, but even 
with <50% of crescents but combined with moderate or severe fibrosis the risk of 
doubled creatinine is high specially in black patients [28].
Renal biopsy does not adequately predict the progression of long-term lesions 
due to disagreement between signs of clinical and histological activity of the 
disease. Patients in clinical remission show in repeated biopsies evidence of active 
inflammatory process. On the other hand, in the absence of histological activity, 
cases of patients with persistent clinical signs are described. Thus, studies have sug-
gested that serial biopsies during maintenance therapy may help in patient monitor-
ing [7]. Alsuwaida et al [29] when analyzing a second renal biopsy at the end of the 
maintenance therapy, demonstrated that persistence of glomerular hypercellularity 
and interstitial inflammation presented a higher risk of doubling serum creatinine. 
Patients with an activity index greater than 2 in the second biopsy showed worse 
renal survival at 10 years and regarding the chronicity index there was a trend for 
better renal survival with a CI lower than 3.
6. Clinical findings and management
In order to prevent CKD, all patients with SLE should be evaluated for kidney 
involvement at initial diagnosis and at follow-up. Assessment of patients with 
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Activity and chronicity indices of lupus nephritis according to National Institutes of Health (NIH).
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and early diagnosis with response to therapy is correlated with better outcome  
[7, 9]. The heterogeneous morphological aspects of the disease is accompanied by 
a variable clinical findings. The different classes of LN guide clinicians in making 
the most appropriate therapeutic decision. A purely mesangial disease sparing the 
peripheral glomerular capillaries (classes I and II) usually have a mild disease with 
low levels of proteinuria and normal renal function. The prognosis is excellent 
and the patients require only conservative treatment. In many patients it is a stable 
lesion that may persist for years. However, it can undergo transformation to a more 
severe injury with increased levels of proteinuria and reduced kidney function [7]. 
LN with capillary loops injuries (classes III and IV) that shows more endocapil-
lar proliferation, necrosis and crescents, with a coexistence of active and chronic 
lesions, have more aggressive disease. Tubular and interstitial lesions are nearly 
universal in diffuse proliferative LN and parallel the distribution of the glomerular 
lesions. Vascular lesions also occur most frequently in the diffuse proliferative 
group. The clinical manifestations are represented by high levels of proteinuria 
with or without nephrotic syndrome and active urinary sediment. In class III renal 
insufficiency is uncommon and the prognosis is variable. In a small percentage of 
patients there is poor outcome which results from progression of class III to class 
IV. The diffuse proliferative LN (class IV) have the most severe and active clinical 
renal presentation, with nephrotic syndrome in up 50% of the patients and various 
degrees of renal insufficiency in greater than 50% of the patients [30, 31]. It is a 
consensus that class IV has a worse prognosis. The proliferative classes with more 
severe active lesions (III and IV) are treated with potent immunosuppression  
[1, 8]. Some investigators proposed that class IV-S is pathogenetically distinct and 
has worse long-term outcome than class IV-G, suggesting important prognostic 
differences [23]. LN class IV-G has predominantly subendothelial deposits and 
endocapillary proliferation and patients with class IV-S much higher rate of seg-
mental fibrinoid necrosis [32]. Segmental and global glomerulosclerosis are the 
consequence of active necrotizing lesions with crescent formation. The prognostic 
significance of class IV-S versus IV-G has been analyzed in other studies and no 
significant differences in outcome were demonstrated [32–34].
All patients with class V LN have proteinuria and 59–70% have the nephrotic 
syndrome. Renal insufficiency is uncommon. Patients with class V are more likely 
to present with renal disease before other systemic features of lupus are apparent. 
When a membranous lesion is associated with the active or chronic lesions of class 
III or IV, both diagnoses are to be reported. Patients with membranous LN (class V) 
may be managed conservatively with antiproteinuric therapy when proteinuria is 
subnephrotic or with immunosuppression with nephrotic proteinuria [7]. Patients 
with class VI lupus nephritis have severe renal insufficiency and require only sup-
portive treatment and/or kidney replacement therapy [7].
7.  Controversial aspects of ISN/RPS classification and NIH activity and 
chronicity indices
The classification of INS/RPS was proposed to standardize and emphasize the 
most relevant lesions to guide the treatment of LN. Recently, several retrospective 
validation studies concerning the utility of the classification were performed. These 
studies have highlighted the limitations of the classification and of the activity 
and chronicity indices. In these reports, the main weaknesses of the classification 
include: 1. Tubulointerstitial and vascular lesions not included in the system; 2. 
No correlation between the lesions with long-term outcome; 3. Poor interobserver 
reproducibility of both active and chronic lesions [12, 13, 32–35].
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Tubulointerstitial and vascular lesions correlated closely with clinical disease 
activity and renal outcome in many studies [14, 19–21]. It is necessary at least to 
mention these lesions in the diagnosis of the biopsy report.
The classification of LN, especially classes IV-G and IV-S, and the activity and 
chronicity indexes have not shown a satisfactory correlation with the long-term 
outcome of the disease [1, 7, 8, 13]. After treatment induction and even during the 
maintenance phase, the inflammatory process may persist and go unnoticed clini-
cally. Some authors recommend repeating the renal biopsy after treatment to better 
assess the response to treatment and predict the course of the disease [1, 7, 8, 29]. 
There is also a poor reproducibility among pathologists to apply these criteria that 
limits their application in practice [1, 36, 37]. It is a consensus that the classifica-
tion of LN as well as the criteria of activity and chronicity of the disease should be 
reviewed [1, 7, 8, 36, 37].
8. Conclusions
In conclusion, the precise identification of key glomerular, tubulointerstitial 
and vascular lesions remain incompletely understood in terms of pathogenesis 
and prognostic effect. The ISN/RPS classification improved the knowledge of 
different patterns of LN lesions, and validation studies have shown new emerging 
morphological data to be further investigated and included in the classification 
[8, 12, 35]. Most nephrologists find an assessment of activity and chronicity 
Biopsy Report
ID: RPS, caucasian, female with 38 years-old
History: Patient with erythema and scaling in the face, lymphocitopenia, anemia, proteinuria of 
2g/24h, microhematuria, serum creatinine of 1,8 mg/dl. Anti-dsDNA>200 UI, ANA 1/1600.
Renal biopsy
Macroscopy: 3 fragments of renal biopsy measuring each 1cm long. One fragment fixated in Duboscq-
Brazil was sent to LM, 1 frozen fragment was sent to IF using anti-IgG, IgA, IgM, C1q, C3, Fibrin, κ and λ 
conjugates, 1 fixated in glutaraldehyde 2,5% sent to EM.
Light Microscopy: Renal biopsy showing the cortical with 30 glomeruli, all with large size and 
mesangioendothelial heavy hypercellularity and moderate exsudate of polymorphonuclear neutrophils; 
some peripheral capillary loops show bulky hyaline deposits obliterating capillary lumens (wire loops). In 
6 glomeruli there are small segments fibrinoid necrosis, nuclear debris and fibrin deposits, with overlying 
small cellular crescents. Two glomeruli are globally sclerosed surrounded by tubular atrophy and mild 
interstitial fibrosis. There is also a heavy interstitial edema and inflammatory infiltrate of mononuclear cells 
with degenerative changes of tubules. The vessels are unremarkable.
Immunofluorescence: Presence of diffuse granular deposits in the mesangium and capillary loops 
of IgG (3/3+), IgA (2/3+), IgM (1/3+), C1q (3/3+), C3 (2/3+), Fibrin (2/3+), κ and λ (2/3+). There were 
deposits in the tubular basement membrane and peritubular capillaries of IgG and C1q (2/3+). There were 
no deposits in the vessels.
Electron microscopy: Presence of mesangial, subendothelial and tubular basement membrane electron-
dense deposits.
Renal biopsy diagnosis: Lupus nephritis characterized by diffuse proliferative glomerulonephritis 
with 20% of segmental necrosis, 20% of cellular crescents and 6,6% of global glomerular sclerosis. Intense 
lymphomononuclear tubulointerstitial nephritis with focal tubular atrophy and interstitial fibrosis. Normal 
vessels.
ISN/RPS classification: Class IV-G (A/C)
NIH Activity and Chronicity Indices:
Activity: subendothelial deposits 2+, glomerular hypercellularity 3+, exsudate of neutrophils 2+, 
necrosis 2+, cellular crescents 2+, interstitial inflammatory infiltrate 3+. Total = 14
Chronicity: glomerular sclerosis 1+, tubular atrophy 1+, interstitial fibrosis 1+. Total =3
Box 1. 
Biopsy Report Interpretation of Lupus Nephritis
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indices useful, and the biopsy reports should include routinely, with a detailed 
description of the types of active and chronic lesions and proportion of glomeruli 
affected (Figures 1–3 and Box 1). Despite these unresolved controversies, active 
lesions versus chronic lesions, in addition to class of LN, influence response to 
therapy. The ISN/RPS recently presented a consensus report from a meeting of 
an international nephropathology working group in 2016. Briefly, they proposed 
new definitions for mesangial hypercellularity and different patterns of crescents; 
endocapillary proliferation was replaced by endocapillary hypercellularity, the 
IV-S and IV-G subclasses were eliminated, and active and chronic designations of 
class III and IV were replaced by the activity and chronicity indices that should be 
applied to all classes. In order to improve the LN classification, further studies will 
be carried out to validate the new proposal [38].
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